Why Tata 1mg thinks speed is the wrong bet in pharma
· 12 min · Episode 819
Episode Why Tata 1mg thinks speed is the wrong bet in pharma
Tata 1mg just reported revenue of nearly 3,000 crore rupees for the last financial year, roughly ten times what it earned when Tata took control, and it is turning a profit while much of the sector bleeds cash.
In an e-pharmacy market obsessed with 10-minute delivery and deep discounts, 1mg won by doing the opposite. It capped its discounts and built its own labs and supply chain, and it treats fast delivery as a minor add-on.
In this episode, we unpack why patience beats blitzscaling in Indian healthcare and what 1mg means when it calls healthcare longitudinal.
Take The Great Rewiring survey here
Daybreak is produced from the newsroom of The Ken, India’s first subscriber-only business news platform. Subscribe for more exclusive, deeply-reported, and analytical business stories.
Links in the notes 2
Shows are listed from Apple Podcasts' charts and directory, and Podcast Index where it is used. Every show and episode belongs to its publisher and plays from the publisher's own feed; this site hosts none of them. Explicit shows are for adult profiles only, and children’s profiles hear only children’s shows. More about this list.